
Carol M. Koslow
Examiner (ID: 12920, Phone: (571)272-1371 , Office: P/1734 )
| Most Active Art Unit | 1734 |
| Art Unit(s) | 1734, 1754, 1793, 1755, 1108 |
| Total Applications | 5011 |
| Issued Applications | 4022 |
| Pending Applications | 258 |
| Abandoned Applications | 784 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15239549
[patent_doc_number] => 20190374560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/450836
[patent_app_country] => US
[patent_app_date] => 2019-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450836
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/450836 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | Jun 23, 2019 | Abandoned |
Array
(
[id] => 16791717
[patent_doc_number] => 20210121534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 17/254617
[patent_app_country] => US
[patent_app_date] => 2019-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21009
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254617
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/254617 | SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | Jun 17, 2019 | Pending |
Array
(
[id] => 15264447
[patent_doc_number] => 20190380957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => Protein Hydrogels For Treatment Of Neovascular Disease
[patent_app_type] => utility
[patent_app_number] => 16/442044
[patent_app_country] => US
[patent_app_date] => 2019-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16442044
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/442044 | Protein Hydrogels For Treatment Of Neovascular Disease | Jun 13, 2019 | Abandoned |
Array
(
[id] => 15649631
[patent_doc_number] => 20200087345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => MODULATION OF P53 FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/422850
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29764
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422850
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/422850 | Modulation of P53 for the treatment of cancer | May 23, 2019 | Issued |
Array
(
[id] => 14864869
[patent_doc_number] => 20190282676
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => HEMOSTATIC COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/421094
[patent_app_country] => US
[patent_app_date] => 2019-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421094
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/421094 | HEMOSTATIC COMPOSITIONS | May 22, 2019 | Abandoned |
Array
(
[id] => 15035653
[patent_doc_number] => 20190328831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1
[patent_app_type] => utility
[patent_app_number] => 16/411944
[patent_app_country] => US
[patent_app_date] => 2019-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10589
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16411944
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/411944 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | May 13, 2019 | Abandoned |
Array
(
[id] => 16868433
[patent_doc_number] => 20210161900
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS
[patent_app_type] => utility
[patent_app_number] => 17/047258
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10686
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047258
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/047258 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SENESCENT TUMOR CELLS | Apr 28, 2019 | Abandoned |
Array
(
[id] => 16596582
[patent_doc_number] => 20210023113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 17/042221
[patent_app_country] => US
[patent_app_date] => 2019-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042221
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/042221 | CONJUGATE OF CYTOTOXIC DRUG AND PRODRUG FORM OF SAID CONJUGATE | Apr 1, 2019 | Pending |
Array
(
[id] => 16343578
[patent_doc_number] => 20200308228
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES
[patent_app_type] => utility
[patent_app_number] => 16/371610
[patent_app_country] => US
[patent_app_date] => 2019-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14610
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16371610
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/371610 | PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES | Mar 31, 2019 | Abandoned |
Array
(
[id] => 14682333
[patent_doc_number] => 20190240281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-08
[patent_title] => ORAL ANAEROBIC GLUTATHIONE SUPPLEMENT IN LIPOSOME SUSPENSION
[patent_app_type] => utility
[patent_app_number] => 16/368057
[patent_app_country] => US
[patent_app_date] => 2019-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16368057
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/368057 | ORAL ANAEROBIC GLUTATHIONE SUPPLEMENT IN LIPOSOME SUSPENSION | Mar 27, 2019 | Abandoned |
Array
(
[id] => 20142857
[patent_doc_number] => 12377172
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => Methods and compositions for the detection of cancer
[patent_app_type] => utility
[patent_app_number] => 16/365166
[patent_app_country] => US
[patent_app_date] => 2019-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 7445
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16365166
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/365166 | Methods and compositions for the detection of cancer | Mar 25, 2019 | Issued |
Array
(
[id] => 15020869
[patent_doc_number] => 20190321439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/356259
[patent_app_country] => US
[patent_app_date] => 2019-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356259
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/356259 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Mar 17, 2019 | Abandoned |
Array
(
[id] => 16539455
[patent_doc_number] => 20200405868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => GEL-FORMING POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/970894
[patent_app_country] => US
[patent_app_date] => 2019-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970894
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/970894 | GEL-FORMING POLYPEPTIDES | Mar 13, 2019 | Abandoned |
Array
(
[id] => 19624156
[patent_doc_number] => 12162960
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Selectin inhibitors, composition, and uses related thereto
[patent_app_type] => utility
[patent_app_number] => 16/352585
[patent_app_country] => US
[patent_app_date] => 2019-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 8450
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352585
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/352585 | Selectin inhibitors, composition, and uses related thereto | Mar 12, 2019 | Issued |
Array
(
[id] => 16539502
[patent_doc_number] => 20200405915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => HYDROGEL FOR STIMULATING NEUROTIZATION, OSTEOGENESIS AND ANGIOGENESIS
[patent_app_type] => utility
[patent_app_number] => 16/976482
[patent_app_country] => US
[patent_app_date] => 2019-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16976482
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/976482 | HYDROGEL FOR STIMULATING NEUROTIZATION, OSTEOGENESIS AND ANGIOGENESIS | Feb 27, 2019 | Pending |
Array
(
[id] => 15206355
[patent_doc_number] => 20190365864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS
[patent_app_type] => utility
[patent_app_number] => 16/266873
[patent_app_country] => US
[patent_app_date] => 2019-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28170
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16266873
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/266873 | TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS | Feb 3, 2019 | Abandoned |
Array
(
[id] => 16655844
[patent_doc_number] => 20210052480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => USE OF CYCLIC PEPTIDES IN COSMETIC
[patent_app_type] => utility
[patent_app_number] => 16/963578
[patent_app_country] => US
[patent_app_date] => 2019-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15760
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963578
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/963578 | USE OF CYCLIC PEPTIDES IN COSMETIC | Jan 28, 2019 | Pending |
Array
(
[id] => 14622025
[patent_doc_number] => 20190224380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-25
[patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING HEALING AND REGENERATION OF BONE AND SOFT TISSUE
[patent_app_type] => utility
[patent_app_number] => 16/249748
[patent_app_country] => US
[patent_app_date] => 2019-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16249748
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/249748 | COMPOSITIONS AND METHODS FOR ENHANCING HEALING AND REGENERATION OF BONE AND SOFT TISSUE | Jan 15, 2019 | Pending |
Array
(
[id] => 14581285
[patent_doc_number] => 20190218251
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION
[patent_app_type] => utility
[patent_app_number] => 16/246398
[patent_app_country] => US
[patent_app_date] => 2019-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22275
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16246398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/246398 | Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation | Jan 10, 2019 | Issued |
Array
(
[id] => 16398781
[patent_doc_number] => 20200339639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => TREATMENT OF FRAGILE X SYNDROME
[patent_app_type] => utility
[patent_app_number] => 16/961345
[patent_app_country] => US
[patent_app_date] => 2019-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14301
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961345
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/961345 | TREATMENT OF FRAGILE X SYNDROME | Jan 9, 2019 | Abandoned |